Megaloblastic Anemia

Medical Experts

Contributor

Doyle

Kelly Doyle, PhD, DABCC, FAACC

Associate Professor of Pathology (Clinical), University of Utah

Medical Director, Special Chemistry and Endocrinology, ARUP Laboratories

Contributor

Frank

Elizabeth L. Frank, PhD, DABCC

Professor of Pathology (Clinical), University of Utah

Medical Director, Analytic Biochemistry, Calculi and Manual Chemistry; Co-Medical Director, Mass Spectrometry, ARUP Laboratories

Megaloblastic anemia, a group of diseases characterized by large red blood cells (RBCs), is a form of macrocytic anemia. The condition results from impaired DNA synthesis and consequent defective erythrocyte maturation. Megaloblastic anemia is common in adults older than 60 years (a demographic group that continues to grow in the United States) and is associated with significant morbidity. Causes of megaloblastic anemia include vitamin B₁₂ (cobalamin) or folate (vitamin B₉) deficiency and specific drugs.^, Vitamin B₁₂ deficiency and associated megaloblastic anemia may be caused by pernicious anemia, in which a lack of intrinsic factor (IF) prevents sufficient absorption of vitamin B₁₂. The initial evaluation for megaloblastic anemia includes a CBC and review of a peripheral blood smear. Additional testing for vitamin B₁₂ and/or folate deficiency and antibody testing for pernicious anemia may be performed based on the results of these initial tests.

Quick Answers for Clinicians

How does megaloblastic anemia present clinically?

Patients with megaloblastic anemia may present with symptoms of anemia such as pale skin and fatigue. In severe cases, atrophy of mucous membranes may occur and result in pain in the mouth; infants may exhibit failure to thrive. There may be jaundice as a result of hemolysis. Patients with megaloblastic anemia due to vitamin B₁₂ deficiency may also present with symptoms of peripheral neuropathy, such as dysesthesia and hypoesthesia. In severe cases, ataxia and other severe peripheral and central nervous system manifestations (eg, changes in mental status) of prolonged vitamin B₁₂ deficiency may be present. However, some patients may be asymptomatic, and certain laboratory features of megaloblastic anemia may be masked by concurrent iron deficiency or microcytic anemia.

Which laboratory test results should prompt testing for megaloblastic anemia?

An evaluation for megaloblastic anemia is often prompted by CBC results. CBC findings may include anemia (hemoglobin <13 g/dL in men and <12 g/dL in women) with macrocytosis (mean corpuscular volume >100 fL). A peripheral blood smear may reveal macro-ovalocytes, anisocytosis, poikilocytosis, and hypersegmented neutrophils, a specific indicator of megaloblastic anemia.^,

What are the possible causes of megaloblastic anemia?

Causes of megaloblastic anemia include vitamin B₁₂ or folate deficiency (as a result of decreased intake, decreased absorption, or increased demand), specific drugs, inborn errors of metabolism, myelodysplastic syndromes, and problems with DNA synthesis (eg, from chemotherapy). However, folate fortification programs are increasingly common and have greatly reduced the prevalence of folate deficiency. There are numerous less common causes, including nitrous oxide exposure and Diphyllobothrium latum infection. Because vitamin deficiency is a major cause of megaloblastic anemia, older individuals, persons who are malnourished, those with alcohol use disorder, and individuals who consume a vegetarian or vegan diet are at increased risk for megaloblastic anemia.

Which drugs are associated with megaloblastic anemia?

Drugs that induce megaloblastic anemia typically interfere with vitamin B₁₂ or folate absorption or metabolism.x These drugs include immunomodulators and antineoplastic agents that act on purine metabolism or pyrimidine synthesis (eg, methotrexate, fluorouracil); antibiotics, hormones, or tuberculosis treatments that interfere with absorption (eg, estrogens, tetracyclines, isoniazid); antimalarial agents; and many others. A detailed medical history is therefore useful in ruling out medication-related megaloblastic anemia.

Indications for Testing

Testing for megaloblastic anemia is used to identify the etiology of macrocytosis and/or clinical features of megaloblastic anemia (eg, neurologic symptoms).^,

Laboratory Testing

Initial Evaluation

For information on the initial evaluation of anemia, see the ARUP Consult Anemia topic.

Testing for megaloblastic anemia is often prompted by the identification of macrocytosis from a CBC; if neurologic symptoms or other clinical features prompt testing, a CBC should be performed. Hemoglobin and hematocrit can be measured to confirm anemia. Once macrocytic anemia has been confirmed, a peripheral smear is recommended.^, Anisocytosis, poikilocytosis, macro-ovalocytes, and hypersegmented neutrophils may be present.^, However, these peripheral smear findings are not diagnostic. A reticulocyte count is also recommended.^, The reticulocyte count is generally low in megaloblastic anemia; therefore, if reticulocytosis is present, consider a workup for hemolysis (including lactate dehydrogenase and bilirubin tests).^,

If megaloblastic anemia is suspected based on clinical features and the results of the CBC and peripheral smear, evaluation for possible drug-induced megaloblastic anemia through a detailed medical history is recommended. If the megaloblastic anemia is not drug induced, testing for vitamin deficiencies should be considered.

Evaluation for Vitamin Deficiency

Vitamin B₁₂ and/or folate deficiency may result in megaloblastic anemia. Because vitamin B₁₂ deficiency is much more common than folate deficiency, the evaluation should commence with tests for vitamin B₁₂, or a combined vitamin B₁₂/folate test can be used.

Vitamin B₁₂ Deficiency Testing

Testing for vitamin B₁₂ deficiency begins with a serum concentration test. Follow-up testing depends on the result of this test. The patient’s use of vitamin B₁₂ injections should be considered when interpreting test results, given that serum vitamin B₁₂ concentration may be affected by injections administered within approximately 2 weeks of specimen collection.

Testing Strategy Based on Serum Vitamin B₁₂ Concentration
Serum Vitamin B₁₂ Concentration	Interpretation	Next Steps
<200 pg/mL	Vitamin B₁₂ deficiency is probable	Evaluation for pernicious anemia is recommended
200-400 pg/mL	Results are borderline	Perform MMA and homocysteine tests; consider evaluation for pernicious anemia
>400 pg/mL	Vitamin B₁₂ deficiency is unlikely^a	Consider testing for folate deficiency
^aIf suspicion for vitamin B₁₂ deficiency persists in a patient with a vitamin B₁₂ concentration >400 pg/mL, consider MMA and homocysteine tests. MMA, methylmalonic acid Source: Green, 2017

The MMA test is a sensitive and specific indicator of vitamin B₁₂ deficiency that can be used if the serum vitamin B₁₂ concentration is borderline. An elevated MMA concentration (>0.4 µmol/L) confirms vitamin B₁₂ deficiency. Plasma homocysteine levels may also be increased in vitamin B₁₂ deficiency, although this test is not specific. If vitamin B₁₂ deficiency is confirmed, evaluation for pernicious anemia is recommended. For additional information on vitamin B₁₂ and MMA tests, see the ARUP Consult Vitamins topic.

Folate Deficiency Testing

Testing for folate deficiency should begin with a serum or plasma folate test. A serum or plasma folate concentration <4 µg/L indicates folate deficiency. If results are not conclusive, an RBC folate test can be performed, followed by a homocysteine test if the concentration of folate is borderline. Although the homocysteine test is not specific, an increased homocysteine level is consistent with folate deficiency. For additional information on these tests, see the ARUP Consult Vitamins topic.

Evaluation for Pernicious Anemia

The majority of patients with pernicious anemia have antibodies for parietal cells and IF. In patients with confirmed vitamin B₁₂ deficiency, testing for pernicious anemia is recommended. In patients with borderline vitamin B₁₂ and MMA test results, this testing is considered optional.

Intrinsic Factor Blocking Antibody Testing

Antibodies to IF are specific to pernicious anemia and are present in the majority of patients. A positive IF antibody test confirms pernicious anemia.

Parietal Cell Antibody Testing

Parietal cell antibody tests are more sensitive than IF antibody tests, but parietal cell antibodies are less specific to pernicious anemia and may be seen in chronic gastritis.^, A positive parietal cell antibody test following a negative IF test in the appropriate clinical context confirms the diagnosis of pernicious anemia.

Serum Gastrin Testing

Gastrin concentration is generally elevated in pernicious anemia but may be increased in other conditions as well. Gastrin testing can be considered to indirectly confirm pernicious anemia if a parietal cell antibody test is negative but suspicion for pernicious anemia persists.

Other Testing

The Schilling test is an obsolete test that measures the enteral absorption of vitamin B₁₂; it is not generally available. The deoxyuridine suppression test uses radioactive deoxyuridine to assess vitamin B₁₂ and folate status. This test may be useful in some patients if other tests fail to diagnose vitamin B₁₂ or folate deficiency. Bone marrow biopsy may also be considered if other tests fail to yield a diagnosis.